Dr. Al-Sawaf on the 5-Year Results of the CLL14 Trial in CLL

Othman Al-Sawaf, MD, physician, the University Hospital of Cologne, discusses the 5-year follow up data from the phase 3 CLL14 trial (NCT02242942) in patients with previously untreated chronic lymphocytic leukemia (CLL) with preexisting conditions.

The open-label, multicenter, randomized study evaluated the efficacy and safety of obinutuzumab (Gazyva) and venetoclax (Venclexta) vs obinutuzumab plus chlorambucil in this patient population.

The 5-year progression-free survival (PFS) rate was 62.6% for patients who received obinutuzumab and venetoclax, compared with 27% in patients administered obinutuzumab plus chlorambucil, Al-Sawaf explains.

Though treatment consisted of only 12 cycles, a majority of the patients remained in remission for more than 4 years after treatment completion, highlighting that a fixed-duration approach is effective in these patients, Al-Sawaf concludes.